Across TCGA pan-cancer cohorts, DAXX mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DAXX data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DAXX mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DAXX expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where DAXX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.669	1.000	.013	4	view →
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
UCEC	OS	Tertile	All	0.919	1.000	.033	2	view →
LUAD	DFS	Quartile	All	0.944	0.553	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: DAXX tumor-vs-normal RNA expression · all DAXX data types